Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Regulatory Effects of Cheunggansoyo-san on Pathophysiological Changes Induced by Hyperlipidemic Diets in the Mice

  • Park Kyung-Ho (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • NamGung Uk (Department of Neurophysiology, College of Oriental Medicine, Daejeon University) ;
  • Lee Yong-Koo (Department of Internal medicine, College of Oriental Medicine, Daejeon University) ;
  • Kang Tak-Lim (Department of Pharmacology, College of Oriental Medicine, Daejeon University) ;
  • Kim Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
  • Published : 2005.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Hyperlipidemia is caused by high dietary intake of cholesterol and saturated fats, and is known as a major risk factor for atherosclerosis. In the oriental medicine, Cheunggansoyo-san (CGSYS) has been used for supplementing hematopoietic function and for treating cardiovascular disorders. In the present study, CGSYS was administered into hyperlipidemic mice. Increases in body weight and cholesterol levels induced by hyperlipidemic diets for 6 weeks were significantly inhibited by CGSYS administration. Serum levels of glucose, triglyceride, SGOT, and SGPT values were all decreased by CGSYS treatment compared with hyperlipidemic dietary mice. Moreover, CGSYS decreased LDL-cholesterol, but increased HDL-cholesterol levels in hyperlipidemic mice. Thus, the present results suggest that CGSYS appears to De effective for down-regulating risk factors of hyperlipidemia.

Keywords

References

  1. Abe, H., Yamada, N., Kamata, K., Kuwaki, T., Shimada, M., Osuga, J., Shionoiri, F., Yahagi, N., Kadowaki, T., Tamemoto, H., Ishibashi, S., Yazaki, Y., Makuuchi, M. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest. 15;101(8):1784-1788, 1998.
  2. Aouizerat, B.E., Allayee, H., Bodnar, J., Krass, K.L., Peltonen, L., de Bruin, T.W., Rotter, J.I., Lusis, A.J. Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol. 10(2):113-122, 1999.
  3. Arafa, H.M. Curcumin attenuates diet-induced hypercholesterolemia in rats. Med Sci Monit. 11(7):228-234, 2005.
  4. Arslan, N., Buyukgebiz, B., Ozturk, Y., Cakmakci, H. Fatty liver in obese children: prevalence and correlation with anthropometric measurements and hyperlipidemia. Turk J Pediatr. 47(1):23-27, 2005.
  5. Ashen, M.D., Blumenthal, R.S. Clinical practice. Low HDL cholesterol levels. N Engl J Med. 22;353(12):1252-1260, 2005.
  6. Chang, W.T., Dao, J., Shao, Z.H. Hawthorn: potential roles in cardiovascular disease. Am J Chin Med. 33(1):1-10, 2005.
  7. Clarkson, T.B. Animal models of atherosclerosis. Adv Vet Sci Comp Med. 16, pp 151-173, 1972.
  8. Cryer, P.E., Daughaday, W.H. Diabetic ketosis: elevated serum glutamic-oxaloacetic transaminase (SGOT) and other findings determined by multi-channel chemical analysis. Diabetes. 18(11):781-785, 1969.
  9. Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P., Garg, R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 22;111(11):1448-1454, 2005.
  10. den Boer, M., Voshol, P.J., Kuipers, F., Havekes, L.M., Romijn, J.A. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol. 24(4):644-649, 2004.
  11. Duplain, H., Burcelin, R., Sartori, C., Cook, S., Egli, M., Lepori, M., Vollenweider, P., Pedrazzini, T., Nicod, P., Thorens, B., Scherrer, U. Insulin resistance, hyperlipidemia,and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 17;104(3):342-345, 2001.
  12. Espirito, Santo, S.M., Rensen, P.C., Goudriaan, J.R., Bensadoun, A., Bovenschen, N., Voshol, P.J., Havekes, L.M., van Vlijmen, B.J. Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor,and LRP triple-deficient mice. J Lipid Res. 46(6):1097-1102, 2005.
  13. Fong, T.M. Targeting metabolic syndrome. Expert Opin Investig Drugs. 13(9):1203-1206, 2004.
  14. Giese, K., Fantl, W.J., Vitt, C., Stephans, J.C., Cousens, L., Wachowicz, M., Williams, L.T. Reduction of food intake and weight gain by the ob protein requires a specific secondary structure and is reversible. Mol Med. 2(1):50-58, 1996.
  15. Herrera, V.L., Makrides, S.C., Xie, H.X., Adari, H., Krauss, R.M., Ryan, U.S., Ruiz-Opazo, N. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med. 5(12):1383-1389, 1999.
  16. Hotamisligil, G.S. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord. 24 Suppl 4, S23-27, 2000.
  17. Inoue, M., Shen, Y.R., Ogihara, Y. Shosaikoto (kampo medicine) protects macrophage function from suppression byhypercholesterolemia. Biol Pharm Bull. 19(4):652-654, 1996.
  18. Jones, P.H. Diet and pharmacologic therapy of obesity to modify atherosclerosis. Curr Atheroscler Rep. 2(4):314-320, 2000.
  19. Jones, P.H. Clinical diagnosis of lipid disorders. Clin Cornerstone. 1(1):15-30, 1998.
  20. Kim. et al. 전국한의과대학 본초학교수 공편저. 본초학. 서울 영림사, 1990.
  21. Kim, S.O., Yun, S.J., Jung, B., Lee, E.H., Hahm, D.H., Shim, I., Lee, H.J. ypolipidemic effects of crude extract of adlay seed (Coix lachrymajobi var.mayuen) in obesity rat fed high fat diet: relations of TNF-alpha and leptin mRNA expressions and serum lipid levels. Life Sci. 75(11):1391-1404, 2004.
  22. Kim, Y.Y., Kang, H.J., Ko, S.K., Chung, S.H. Sopungsungi-won (SP) prevents the onset of hyperglycemia and hyperlipidemia in Zucker diabetic fatty rats. Arch Pharm Res. 25(6):923-931, 2002.
  23. Krause, B.R., Princen, H.M. Lack of predictability of classical animal models for hypolipidemic activity: agood time for mice? Atherosclerosis. 140(1):15-24, 1998.
  24. la Cour, B., Molgaard, P., Yi, Z. Traditional Chinese medicine in treatment of hyperlipidaemia. J Ethnopharmacol. 46(2):125-129, 1995.
  25. Masucci-Magou1as, L., Goldberg.. I.J., Bisgaier, C.L., Serajuddin, H., Francone, O.L., Breslow, J.L., Tal, A.R. A mouse model with features of familial combined hyperlipidemia. Science. 275(5298):391-394, 1997.
  26. Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J., Seckl, J.R., Flier, J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science. 294(5549):2166-2170, 2001.
  27. Molnar, J., Yu, S., Mzhavia, N., Pau, C., Chereshnev, I., Dansky, H.M. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ Res. 96(11):1178-1184, 2005.
  28. Paigen, B., Plump, A.S., Rubin, E.M. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr Opin Lipidol. 5(4):258-264, 1994.
  29. Pedrinelli, R., Esposti, E.D., Dell'Omo, G. LDL cholesterol and global risk stratification in referred hypertensive patients. Atherosclerosis. 180(1):137-143, 2005.
  30. Ponder, K.P. Systemic gene therapy for cardiovascular disease. Trends Cardiovasc Med. 9(6):158-162, 1999.
  31. Powell-Braxton, L., Veniant, M., Latvala, R.D., Hirano, K.I., Won, W.B., Ross, J., Dybda, I.N., Zlot, C.H., Young, S.G., Davidson, N.O. A mouse model of human familial hypercholesterolemia: markedly elevated lowdensity lipoprotein cholesterol levels and severe atherosclerosis on a low-fatchow diet. Nat Med. 4(8):934-938, 1998.
  32. Quaschning, T., Schomig, M., Keller, M., Thiery, J., Nauck, M., Schollmeyer, P., Wanner, C., Kramer-Guth, A. Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impairlipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol. 10(2):332-341, 1999.
  33. Rao, P.N., Rao, G.V. Transaminases of serum & tissues in ypercholesteremia. Indian J Exp Biol. 17(7):665-667, 1979.
  34. Rubin, D.C. Nutrient absorption. Curr Opin Gastroenterol. 20(2):65-69, 2004.
  35. Saltiel, A.R., Kahn, C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414(6865):799-806, 2001.
  36. Scheuch, K., Hanefeld, M., Grassier, J., Seibt, R., Naumann, H.J. ypertriglyceridaemia in mild hypertension: impact on cardiovascular andhormonal reactivity under different stress tests. J Hum Hypertens. 13(8):533-539, 1999.
  37. Takahashi, N., Qi, Y., Patel, H.R., Ahima, R.S. A novel aminosterol reverses diabetes and fatty liver disease in obese mice. J Hepatol. 41(3):391-398, 2004.
  38. Vischer, U.M. Hyperglycemia and the pathogenesis of atherosclerosis: lessons from murine models. Eur J Endocrinol. 140(1):1-3, 1999.
  39. Wexle,r B.C., lams, S.G., McMurtry, J.P. Pathophysiological differences between obese and non-obese spontaneously hypertensive rats. Br J Exp Pathol. 61(2):195-207, 1980.
  40. Wiklund, O., Angelin, B., Fager, G., Eriksson, M., Olofsson, S.O., Berglund, L., Linden, T., Sjoberg, A., Bondjers, G. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med. 228(3):241-247, 1990.
  41. Zuccala, A. Dyslipidemia and hypertension: twin killers in renal vascular disease. Am J Kidney Dis. 37(6):1319-1323, 2001. https://doi.org/10.1053/ajkd.2001.23667